Ye Li, Sun Xiwei, Li Yiping, Zeng Yali, Zhuoma Lacuo, Zhou Dinglun, He Qinying, Wang Ju, Yang Wei, Yu Hang, Yang Yihui, Liang Shu, Yuan Dan
Center for AIDS/STD Control and Prevention, Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan, People's Republic of China.
West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Infect Drug Resist. 2024 Jul 18;17:3133-3143. doi: 10.2147/IDR.S463262. eCollection 2024.
Sichuan Province was severely affected by the HIV, and there was a scarcity of data regarding the survival time and influencing factors for People Living with HIV/AIDS (PLWH) in Sichuan Province who have received Antiretroviral Therapy (ART). Therefore, it is necessary to conduct a survival analysis for PLWH receiving ART.
A retrospective cohort study was conducted on PLWH who had received ART≥6 months in Sichuan Province from January 1, 2003, to December 31, 2022. The Kaplan-Meier method was used to calculate median survival time and plot survival curves, while a Cox proportional hazards regression model was applied to analyze factors affecting survival time. Bilateral tests were performed, with P≤0.05 considered statistically significant.
The cumulative survival rates at 1, 3, 5, and 10 years for the 223,386 subjects were 94.54%, 89.07%, 84.82%, and 76.44%, respectively. Multivariate analysis using the Cox regression model indicated lower mortality risks for females (HR=0.59, 95% CI: 0.54-0.65), homosexual transmission (HR=0.43, 95% CI: 0.33-0.55), and baseline BMI≥24 (HR=0.81, 95% CI: 0.72-0.90). Higher mortality risks were associated with age≥50 years at diagnosis (HR=3.21, 95% CI: 2.94-3.50), being unmarried or divorced (HR=1.23, 95% CI: 1.11-1.37), living separately (HR=1.32, 95% CI: 1.22-1.43), baseline BMI <18.5 (HR=1.27, 95% CI: 1.13-1.41), presence of single-drug resistance (HR=1.25, 95% CI: 1.15-1.36), baseline WHO stage IV (HR=1.27, 95% CI: 1.09-1.47), and a diagnosis-to-treatment interval >12 months (HR=1.27, 95% CI: 1.15-1.41). Compared to those with CD4(+) T cell count of 200-350cells/μL, 350-500cells/μL, and >500cells/μL at baseline, individuals with <200cells/μL had higher mortality risks (HR=0.73, 95% CI: 0.67-0.79; HR=0.57, 95% CI: 0.51-0.64; and HR=0.58, 95% CI: 0.51-0.66, respectively).
The survival rate for PLWH receiving ART in Sichuan Province was relatively high. Male gender, age over 50 at diagnosis, being unmarried, divorced, or living separately, presence of single-drug resistance, low baseline BMI, baseline CD4+ T cell <200cells/μL, baseline WHO stage IV, and a diagnosis-to-treatment interval >12 months were risk factors for the survival of PLWH.
四川省受艾滋病病毒影响严重,关于四川省接受抗逆转录病毒治疗(ART)的艾滋病病毒感染者/艾滋病患者(PLWH)的生存时间及影响因素的数据匮乏。因此,有必要对接受ART的PLWH进行生存分析。
对2003年1月1日至2022年12月31日期间在四川省接受ART≥6个月的PLWH进行回顾性队列研究。采用Kaplan-Meier方法计算中位生存时间并绘制生存曲线,同时应用Cox比例风险回归模型分析影响生存时间的因素。进行双侧检验,P≤0.05认为具有统计学意义。
223386名受试者1年、3年、5年和10年的累积生存率分别为94.54%、89.07%、84.82%和76.44%。使用Cox回归模型进行的多变量分析表明,女性(HR=0.59,95%CI:0.54-0.65)、同性恋传播(HR=0.43,95%CI:0.33-0.55)和基线BMI≥24(HR=0.81,95%CI:0.72-0.90)的死亡风险较低。较高的死亡风险与诊断时年龄≥50岁(HR=3.21,95%CI:2.94-3.50)、未婚或离异(HR=1.23,95%CI:1.11-1.37)、独居(HR=1.32,95%CI:1.22-1.43)、基线BMI<18.5(HR=1.27,95%CI:1.13-1.41)、存在单药耐药(HR=1.25,95%CI:1.15-1.36)、基线WHO分期IV期(HR=1.27,95%CI:1.09-1.47)以及诊断至治疗间隔>12个月(HR=1.27,95%CI:1.15-1.41)相关。与基线CD4(+)T细胞计数为200-350个细胞/μL、350-500个细胞/μL和>500个细胞/μL的个体相比,<200个细胞/μL的个体死亡风险更高(HR分别为0.73,95%CI:0.67-0.79;HR为0.57,95%CI:0.51-0.64;HR为0.58,95%CI:0.51-0.66)。
四川省接受ART的PLWH生存率相对较高。男性、诊断时年龄超过50岁、未婚、离异或独居、存在单药耐药、基线BMI低、基线CD4+T细胞<200个细胞/μL、基线WHO分期IV期以及诊断至治疗间隔>12个月是PLWH生存的危险因素。